Renal Function in Type 2 Diabetes Following Gastric Bypass

Area of Science:

• Nephrology
• Endocrinology
• Bariatric Surgery

Background:

• Metabolic surgery, like Roux-en-Y gastric bypass (RYGB), achieves high remission rates for type 2 diabetes (T2D) in obese patients.
• Effects of RYGB on diabetes-associated complications, particularly nephropathy, remain understudied, especially in moderately obese individuals (BMI 25-35 kg/m²).
• Previous research suggests RYGB may improve diabetic neuropathy in this patient group.

Purpose of the Study:

• To investigate the impact of RYGB surgery on diabetic nephropathy progression.
• To assess changes in renal function markers following RYGB in insulin-dependent T2D patients with moderate obesity.

Main Methods:

• A pilot study included 20 insulin-dependent T2D patients (BMI 25-35 kg/m²) with inadequately controlled diabetes.
• All participants underwent a standardized RYGB procedure.
• Renal function was evaluated through blood and urine tests pre-surgery and at 12 and 24 months post-surgery.

Main Results:

• Serum creatinine levels decreased significantly at 12 months post-RYGB (p=0.0025) and remained stable.
• Estimated glomerular filtration rate (eGFR) increased significantly over 24 months (p=0.0093).
• Urinary markers of kidney damage, including albumin/creatinine and adiponectin/creatinine ratios, showed marked reductions (p=0.0491 and p=0.0392, respectively).

Conclusions:

• RYGB demonstrates beneficial effects on renal function in moderately obese, insulin-dependent T2D patients.
• The findings suggest RYGB could be a viable treatment option for this population with uncontrolled T2D.
• Further confirmation through randomized, controlled trials with extended follow-up is warranted.